EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS

被引：0
|
作者：
Touma, Zahi [1 ]
Gladman, Dafna D. [1 ]
Rose, Shawn [2 ]
Fei, Kaiyin [2 ]
Gregan, Y. Irene [2 ]
Gordon, Robert [2 ]
Lo, Kim Hung [2 ]
Urowitz, Murray B. [1 ]
机构：
[1] Univ Toronto, Krembil Res Inst, Toronto, ON, Canada
[2] Janssen Res & Dev LLC, Spring House, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0250
引用
收藏
页码：402 / 403
页数：2
相关论文
共 14 条
  • [1] Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus
    Touma, Zahi
    Gladman, Dafna
    Rose, Shawn
    Fei, Kaiyin
    Gregan, Yun
    Gordon, Robert
    Lo, Kim Hung
    Urowitz, Murray
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] PERFORMANCE OF SLEDAI-2K RESPONDER INDEX-50 IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Touma, Zahi
    Gladman, Dafna
    Fei, Kaiyin
    Gregan, Irene
    Zazzetti, Federico
    Gordon, Robert
    Lo, Kim Hung
    Rose, Shawn
    Urowitz, Murray
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S39 - S39
  • [3] SLEDAI-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
    Touma, Zahi
    Urowitz, Murray
    Gladman, Dafna D.
    Wagner, Carrie
    Zhou, Bei
    Gordon, Robert
    Hsu, Benjamin
    Chevrier, Marc
    Rose, Shawn
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [4] Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) Responder Index (SRI)-50: a Valid Index for Measuring Improvement in Disease Activity
    Touma, Zahi
    Gladman, Dafna
    Ibanez, Dominique
    Urowitz, Murray
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1169 - 1170
  • [5] Development and Assessment of User Satisfaction of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index-50 (SRI-50) Website with Computer-Adaptive Training and Examination Modules
    Touma, Zahi
    Gladman, Dafna
    Mackinnon, Anne
    Carette, Simon
    Abu-Shakra, Mahmoud
    Askanase, Anca
    Nived, Ola
    Hanly, John
    Landolt-Marticorena, Carolina
    Tam, Lai-Shan
    Toloza, Sergio
    Nikpour, Mandana
    Riddell, Claire
    Steiman, Amanda
    Eder, Lihi
    Haddad, Amir
    Barber, Claire
    Urowitz, Murray B.
    [J]. JOURNAL OF RHEUMATOLOGY, 2012, 39 (08) : 1711 - 1711
  • [6] Retrospective Validation of the 3 Laboratory Organ Systems of Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Responder Index (SRI-50) Over 10 Years
    Touma, Zahi
    Gladman, Dafna D.
    Ibanez, Dominique
    Urowitz, Murray B.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S535 - S535
  • [7] Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
    Kim, Alfred
    Strand, Vibeke
    Mathis, Nancy
    Sen, Deepali
    Miner, Jonathan
    Schramm, Elizabeth
    Bruchas, Robin
    Staten, Nick
    Olson, Paul
    Stiening, Chad
    Atkinson, John
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Determining the Minimal Clinically Important Difference for Improvement for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)
    Touma, Zahi
    Gladman, Dafna D.
    Beaton, Dorcas
    Su, Jiandong
    Urowitz, Murray
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] CIRCULATING LEVELS OF IC3B AND C3 LEVELS CORRELATE WITH SLEDAI-2K RESPONDER INDEX-50 (S2K RI-50) DISEASE ACTIVITY SCORES - THE CASTLE (COMPLEMENT ACTIVATION SIGNATURES IN SYSTEMIC LUPUS ERYTHEMATOSUS) STUDY
    Kim, A. H.
    Strand, V.
    Mathis, N.
    Fairweather, W. R.
    Sen, D. P.
    Sinclair, K. C.
    Miner, J. J.
    Schramm, E. C.
    Bruchas, R. R.
    Staten, N.
    Olson, P.
    Stiening, C. M.
    Atkinson, J. P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 814 - 815
  • [10] Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
    Furie, Richard A.
    Kalunian, Kenneth
    Morand, Eric
    Bruce, Ian
    Manzi, Susan
    Tanaka, Yoshiya
    Withrop, Kevin
    Hupka, Ihor
    Hultquist, Micki
    Tummala, Raj
    Abreu, Gabriel
    Lindholm, Catharina
    Al-Mossawi, Hussein
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1184 - 1186
12